## INTRAVENOUS-TO-ORAL CONVERSION FOR ANTIMICROBIALS

>### Benefits of oral therapy:
>* Allows for earlier discharge and reduced length of hospitalisation  
>* Decreases complications related to intravenous (IV) access  
>* Reduces administration and preparation time for IV antibiotics  
>* Reduces drug and related healthcare costs  

>### Criteria for iv-to-oral conversion:
>1. Able to tolerate oral intake i.e. on oral medications/ diet/ enteral feeds, no nausea or vomiting  
>2. Able to absorb medication i.e. no severe diarrhea, GI obstruction, ileus or other GI motility disorder  
>3. Shows signs of clinical improvement, e.g. downward trends for fever and white blood cell count, vital signs are stable  
>4. Not fasting for surgery where oral medication is contraindicated


>### IV-to-oral conversion generally not recommended for:
>* Meningitis / Encephalitis  
>* Acute osteomyelitis / Septic arthritis  
>* Endocarditis  
>* Bacteraemia  
>* Inadequately drained deep-seated abscess (e.g. intra-abdominal, pelvic abscesses)  
>* Liver abscess

>### Antimicrobials suitable for IV-to-PO conversion:
>**1. Ciprofloxacin:**  
Bioavailability 60-85%; IV dose 200-400mg q8-12h; Switch to PO dose 250-750mg BD  
> 
>**2. Moxifloxacin:**  
Bioavailability 86-92%; IV dose 400mg daily; Switch to PO dose 400mg daily  
> 
>**3. Clindamycin:**  
Bioavailability 90%; IV dose 300-600mg q6-8h; Switch to PO dose 300-600mg BD-QDS  
> 
>**4. Co-trimoxazole  (sulphamethoxazole +trimethoprim [TMP]):**  
Bioavailability 90-100%; IV dose 960mg q12h or 5 mg/kg (TMP) q6-12h; Switch to PO dose 960mg (2 tabs) BD or 
5mg/kg (TMP) BD-QDS  
> 
>**5. Metronidazole**  
Bioavailability 100%; IV dose 500mg q8-12h; Switch to PO dose 400mg BD-TDS  
> 
>**6. Linezolid**  
Bioavailability 100%; IV dose 600mg q12h; Switch to PO dose 600mg BD  
> 
>**7. Fluconazole**  
Bioavailability >90%; IV dose 100-800mg daily; Switch to PO dose 100-800mg daily
